Scancell Gains FDA Clearance for Phase 3 Trial of Melanoma Drug Candidate

Scancell Holdings Plc has received U.S. Food and Drug Administration clearance to proceed with a global Phase 3 clinical trial for its investigational cancer vaccine, SCIB1, in melanoma patients. The regulatory milestone allows the company to advance its lead candidate toward potential commercialization. The planned trial will evaluate SCIB1 in patients with Stage III or IV melanoma who have had their tumors surgically removed. The clearance follows earlier Phase 2 data. Scancell stated the FDA feedback provides a clear pathway for the trial's design and endpoints, which are required for a future marketing application.